Advanced search
1 file | 774.05 KB Add to list

Tissue inhibitor metalloproteinase-2 (TIMP-2)∙IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI

Author
Organization
Abstract
Tissue inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for risk stratification in AKI. However, the association of urinary TIMP-2 and IGFBP7 with long-term outcomes is unknown. We evaluated the 9-month incidence of a composite end point of all-cause mortality or the need for RRT in a secondary analysis of a prospective observational international study of critically ill adults. Two predefined [TIMP-2][IGFBP7] cutoffs (0.3 for high sensitivity and 2.0 for high specificity) for the development of AKI were evaluated. Cox proportional hazards models were used to determine risk for the composite end point. Baseline [TIMP-2][IGFBP7] values were available for 692 subjects, of whom 382 (55.2%) subjects developed stage 1 AKI (defined by Kidney Disease Improving Global Outcomes guidelines) within 72 hours of enrollment and 217 (31.4%) subjects met the composite end point. Univariate analysis showed that [TIMP-2][IGFBP7]>2.0 was associated with increased risk of the composite end point (hazard ratio [HR], 2.11; 95% confidence interval [95% CI], 1.37 to 3.23; P<0.001). In a multivariate analysis adjusted for the clinical model, [TIMP-2][IGFBP7] levels>0.3 were associated with death or RRT only in subjects who developed AKI (compared with levels0.3: HR, 1.44; 95% CI, 1.00 to 2.06 for levels>0.3 to 2.0; P=0.05 and HR, 2.16; 95% CI, 1.32 to 3.53 for levels>2.0; P=0.002). In conclusion, [TIMP-2][IGFBP7] measured early in the setting of critical illness may identify patients with AKI at increased risk for mortality or receipt of RRT over the next 9 months.
Keywords
SENESCENCE, IDENTIFICATION, MORTALITY, CARDIAC-SURGERY, ENDOTHELIAL-CELLS, CISPLATIN CYTOTOXICITY, CELL-CYCLE, CRITICALLY-ILL PATIENTS, CYCLE ARREST BIOMARKERS, ACUTE KIDNEY INJURY, kidney, mortality, epidemiology and outcomes

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 774.05 KB

Citation

Please use this url to cite or link to this publication:

MLA
Koyner, Jay L et al. “Tissue Inhibitor Metalloproteinase-2 (TIMP-2)∙IGF-binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-term Outcomes in Patients with AKI.” JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 26.7 (2015): 1747–1754. Print.
APA
Koyner, J. L., Shaw, A. D., Chawla, L. S., Hoste, E., Bihorac, A., Kashani, K., Haase, M., et al. (2015). Tissue inhibitor metalloproteinase-2 (TIMP-2)∙IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 26(7), 1747–1754.
Chicago author-date
Koyner, Jay L, Andrew D Shaw, Lakhmir S Chawla, Eric Hoste, Azra Bihorac, Kianoush Kashani, Michael Haase, Jing Shi, and John A Kellum. 2015. “Tissue Inhibitor Metalloproteinase-2 (TIMP-2)∙IGF-binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-term Outcomes in Patients with AKI.” Journal of the American Society of Nephrology 26 (7): 1747–1754.
Chicago author-date (all authors)
Koyner, Jay L, Andrew D Shaw, Lakhmir S Chawla, Eric Hoste, Azra Bihorac, Kianoush Kashani, Michael Haase, Jing Shi, and John A Kellum. 2015. “Tissue Inhibitor Metalloproteinase-2 (TIMP-2)∙IGF-binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-term Outcomes in Patients with AKI.” Journal of the American Society of Nephrology 26 (7): 1747–1754.
Vancouver
1.
Koyner JL, Shaw AD, Chawla LS, Hoste E, Bihorac A, Kashani K, et al. Tissue inhibitor metalloproteinase-2 (TIMP-2)∙IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2015;26(7):1747–54.
IEEE
[1]
J. L. Koyner et al., “Tissue inhibitor metalloproteinase-2 (TIMP-2)∙IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI,” JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 26, no. 7, pp. 1747–1754, 2015.
@article{7102376,
  abstract     = {Tissue inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for risk stratification in AKI. However, the association of urinary TIMP-2 and IGFBP7 with long-term outcomes is unknown. We evaluated the 9-month incidence of a composite end point of all-cause mortality or the need for RRT in a secondary analysis of a prospective observational international study of critically ill adults. Two predefined [TIMP-2][IGFBP7] cutoffs (0.3 for high sensitivity and 2.0 for high specificity) for the development of AKI were evaluated. Cox proportional hazards models were used to determine risk for the composite end point. Baseline [TIMP-2][IGFBP7] values were available for 692 subjects, of whom 382 (55.2%) subjects developed stage 1 AKI (defined by Kidney Disease Improving Global Outcomes guidelines) within 72 hours of enrollment and 217 (31.4%) subjects met the composite end point. Univariate analysis showed that [TIMP-2][IGFBP7]>2.0 was associated with increased risk of the composite end point (hazard ratio [HR], 2.11; 95% confidence interval [95% CI], 1.37 to 3.23; P<0.001). In a multivariate analysis adjusted for the clinical model, [TIMP-2][IGFBP7] levels>0.3 were associated with death or RRT only in subjects who developed AKI (compared with levels0.3: HR, 1.44; 95% CI, 1.00 to 2.06 for levels>0.3 to 2.0; P=0.05 and HR, 2.16; 95% CI, 1.32 to 3.53 for levels>2.0; P=0.002). In conclusion, [TIMP-2][IGFBP7] measured early in the setting of critical illness may identify patients with AKI at increased risk for mortality or receipt of RRT over the next 9 months.},
  author       = {Koyner, Jay L and Shaw, Andrew D and Chawla, Lakhmir S and Hoste, Eric and Bihorac, Azra and Kashani, Kianoush and Haase, Michael and Shi, Jing and Kellum, John A},
  issn         = {1046-6673},
  journal      = {JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY},
  keywords     = {SENESCENCE,IDENTIFICATION,MORTALITY,CARDIAC-SURGERY,ENDOTHELIAL-CELLS,CISPLATIN CYTOTOXICITY,CELL-CYCLE,CRITICALLY-ILL PATIENTS,CYCLE ARREST BIOMARKERS,ACUTE KIDNEY INJURY,kidney,mortality,epidemiology and outcomes},
  language     = {eng},
  number       = {7},
  pages        = {1747--1754},
  title        = {Tissue inhibitor metalloproteinase-2 (TIMP-2)∙IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI},
  url          = {http://dx.doi.org/10.1681/ASN.2014060556},
  volume       = {26},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: